Biogen’s newly approved Alzheimer’s drug Aduhelm could cost Medicare billions of dollars a year, a new Kaiser Family Foundation report found. The drug has a list price of $56,000 a year, Biogen announced earlier this week. (CNBC Weekly)

French President Emmanuel Macron announced that he supports waiving vaccine patents as part of a global vaccine strategy. Ahead of the G7 Summit, Macron emphasized the importance of “dose sharing” and “opening up of intellectual property.” (Politico)

Bristol Myers Squibb’s CAR-T therapy Breyanzi proved to be effective in patients with relapsed or refractory large B cell lymphoma. The company released topline data from its Phase III TRANSFORM study. (Endpoints News)

The Global Polio Eradication Initiative announced a new $5.1 billion plan that aims to eradicate the disease by 2026. The plan will focus on merging polio programs with other healthcare programs and targeting low immunization areas. (The New York Times)

The National Institutes of Health released a new plan on Thursday to tackle structural racism in biomedical research. The agency said it would expand a program to bring in more researchers from minority groups, but critics say the plan isn’t enough – and are calling on the agency to invest more funding. (STAT)